{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:24:08Z","timestamp":1787847848317,"version":"build-2784847793"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Neurological diseases such as stroke, Alzheimer\u2019s disease, Parkinson\u2019s disease, and Huntington\u2019s disease are among the intractable diseases for which appropriate drugs and treatments are lacking. Proteolysis targeting chimera (PROTAC) technology is a novel strategy to solve this problem. PROTAC technology uses the ubiquitin-protease system to eliminate mutated, denatured, and harmful proteins in cells. It can be reused, and utilizes the protein destruction mechanism of the cells, thus making up for the deficiencies of traditional protein degradation methods. It can effectively target and degrade proteins, including proteins that are difficult to identify and bind. Therefore, it has extremely important implications for drug development and the treatment of neurological diseases. At present, the targeted degradation of mutant BTK, mHTT, Tau, EGFR, and other proteins using PROTAC technology is gaining attention. It is expected that corresponding treatment of nervous system diseases can be achieved. This review first focuses on the recent developments in PROTAC technology in terms of protein degradation, drug production, and treatment of central nervous system diseases, and then discusses its limitations. This review will provide a brief overview of the recent application of PROTAC technology in the treatment of central nervous system diseases.<\/jats:p>","DOI":"10.4103\/1673-5374.308075","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T15:09:31Z","timestamp":1613660971000},"page":"1944-1949","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":22,"title":["Proteolysis targeting chimera technology: a novel strategy for treating diseases of the central nervous system"],"prefix":"10.4103","volume":"16","author":[{"given":"Ke","family":"Ma","sequence":"first","affiliation":[{"name":"College of Life Science, Nantong University, Nantong, Jiangsu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Xiao","family":"Han","sequence":"additional","affiliation":[{"name":"Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Jiangsu Clinical Medicine Center of Tissue Engineering and Nerve Injury Repair, Co-Innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ming","family":"Yang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Jiangsu Clinical Medicine Center of Tissue Engineering and Nerve Injury Repair, Co-Innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8598-0922","authenticated-orcid":false,"given":"Song-Lin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Jiangsu Clinical Medicine Center of Tissue Engineering and Nerve Injury Repair, Co-Innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,10]]},"reference":[{"key":"R1-20260526","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrc.2016.114","article-title":"From Krebs to clinic: glutamine metabolism to cancer therapy","volume":"16","author":"Altman","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"R2-20260526","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","article-title":"A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo","volume":"36","author":"Bai","year":"2019","journal-title":"Cancer Cell"},{"key":"R3-20260526","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat Chem Biol"},{"key":"R4-20260526","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1002\/anie.201307761","article-title":"Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system","volume":"53","author":"Buckley","year":"2014","journal-title":"Angew Chem Int Ed Engl"},{"key":"R5-20260526","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1021\/acschembio.5b00442","article-title":"HaloPROTACS: Use of small molecule PROTACs to induce degradation of halotag fusion proteins","volume":"10","author":"Buckley","year":"2015","journal-title":"ACS Chem Biol"},{"key":"R6-20260526","doi-asserted-by":"crossref","first-page":"11269","DOI":"10.1021\/acs.chemrev.7b00077","article-title":"Small-molecule modulation of protein homeostasis","volume":"117","author":"Burslem","year":"2017","journal-title":"Chem Rev"},{"key":"R7-20260526","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/acs.jmedchem.7b01272","article-title":"Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones","volume":"61","author":"Churcher","year":"2018","journal-title":"J Med Chem"},{"key":"R8-20260526","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1021\/acs.jmedchem.7b01333","article-title":"Inducing protein degradation as a therapeutic strategy","volume":"61","author":"Crews","year":"2018","journal-title":"J Med Chem"},{"key":"R9-20260526","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40265-016-0674-0","article-title":"Insulin resistance and neurodegeneration: progress towards the development of new therapeutics for Alzheimer\u2019s disease","volume":"77","author":"de la Monte","year":"2017","journal-title":"Drugs"},{"key":"R10-20260526","doi-asserted-by":"crossref","first-page":"64431","DOI":"10.18632\/oncotarget.7043","article-title":"Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer","volume":"7","author":"de Melo Gagliato","year":"2016","journal-title":"Oncotarget"},{"key":"R11-20260526","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuint.2019.03.004","article-title":"Neuroprotective effects of targeting BET proteins for degradation with dBET1 in aged mice subjected to ischemic stroke","volume":"127","author":"DeMars","year":"2019","journal-title":"Neurochem Int"},{"key":"R12-20260526","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbrc.2018.02.096","article-title":"Selective degradation of BET proteins with dBET1 a proteolysis-targeting chimera, potently reduces pro-inflammatory responses in lipopolysaccharide-activated microglia","volume":"497","author":"DeMars","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"R13-20260526","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tips.2020.04.005","article-title":"Emerging new concepts of degrader technologies","volume":"41","author":"Ding","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"R14-20260526","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2174\/1570159X16666180222155833","article-title":"The role of inflammatory response in stroke associated programmed cell death","volume":"16","author":"Duris","year":"2018","journal-title":"Curr Neuropharmacol"},{"key":"R15-20260526","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrm.2016.143","article-title":"Functions of bromodomain-containing proteins and their roles in homeostasis and cancer","volume":"18","author":"Fujisawa","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R16-20260526","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat Chem Biol"},{"key":"R17-20260526","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.molcel.2017.02.027","article-title":"The BET protein BRD2 cooperates with CTCF to enforce transcriptional and architectural boundaries","volume":"66","author":"Hsu","year":"2017","journal-title":"Mol Cell"},{"key":"R18-20260526","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1042\/EBC20170041","article-title":"Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders","volume":"61","author":"Hughes","year":"2017","journal-title":"Essays Biochem"},{"key":"R19-20260526","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1021\/acsmedchemlett.9b00283","article-title":"Treatment of cancer and Alzheimer\u2019s disease by PROTAC degradation of EGFR","volume":"10","author":"Kargbo","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"R20-20260526","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1021\/acsmedchemlett.0c00192","article-title":"PROTAC compounds targeting \u03b1-synuclein protein for treating neurogenerative disorders: Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"11","author":"Kargbo","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"R21-20260526","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"R22-20260526","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1021\/acscentsci.6b00280","article-title":"Protein degradation by in-cell self-assembly of proteolysis targeting chimeras","volume":"2","author":"Lebraud","year":"2016","journal-title":"ACS Cent Sci"},{"key":"R23-20260526","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1126\/science.aav2588","article-title":"Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion","volume":"366","author":"Leone","year":"2019","journal-title":"Science"},{"key":"R24-20260526","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-019-1722-1","article-title":"Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds","volume":"575","author":"Li","year":"2019","journal-title":"Nature"},{"key":"R25-20260526","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"key":"R26-20260526","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem Biol"},{"key":"R27-20260526","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejmech.2018.01.063","article-title":"Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway","volume":"146","author":"Lu","year":"2018","journal-title":"Eur J Med Chem"},{"key":"R28-20260526","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"R29-20260526","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41589-018-0055-y","article-title":"Plasticity in binding confers selectivity in ligand-induced protein degradation","volume":"14","author":"Nowak","year":"2018","journal-title":"Nat Chem Biol"},{"key":"R30-20260526","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/1673-5374.224362","article-title":"Modulation of mitochondrial bioenergetics as a therapeutic strategy in Alzheimer\u2019s disease","volume":"13","author":"Onyango","year":"2018","journal-title":"Neural Regen Res"},{"key":"R31-20260526","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.4103\/1673-5374.213532","article-title":"Optogenetics and its application in neural degeneration and regeneration","volume":"12","author":"Ordaz","year":"2017","journal-title":"Neural Regen Res"},{"key":"R32-20260526","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab"},{"key":"R33-20260526","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs) - Past present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov Today Technol"},{"key":"R34-20260526","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"R35-20260526","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41467-018-08027-7","article-title":"Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase","volume":"10","author":"Smith","year":"2019","journal-title":"Nat Commun"},{"key":"R36-20260526","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41375-019-0440-x","article-title":"Degradation of Bruton\u2019s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas","volume":"33","author":"Sun","year":"2019","journal-title":"Leukemia"},{"key":"R37-20260526","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Sun","year":"2018","journal-title":"Cell Res"},{"key":"R38-20260526","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"R39-20260526","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1126\/science.1194653","article-title":"Tau reduction prevents Abeta-induced defects in axonal transport","volume":"330","author":"Vossel","year":"2010","journal-title":"Science"},{"key":"R40-20260526","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/s41589-019-0379-2","article-title":"Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation","volume":"15","author":"Wang","year":"2019","journal-title":"Nat Chem Biol"},{"key":"R41-20260526","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"key":"R42-20260526","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.molcel.2017.06.004","article-title":"BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment","volume":"67","author":"Winter","year":"2017","journal-title":"Mol Cell"},{"key":"R43-20260526","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1021\/acs.jmedchem.6b01781","article-title":"A \u201cClick Chemistry Platform\u201d for the rapid synthesis of bispecific molecules for inducing protein degradation","volume":"61","author":"Wurz","year":"2018","journal-title":"J Med Chem"},{"key":"R44-20260526","doi-asserted-by":"crossref","first-page":"9471","DOI":"10.1021\/acs.jmedchem.9b00846","article-title":"Simple structural modifications converting a bona fide MDM2 PROTAC degrader into a molecular glue molecule: a cautionary tale in the design of PROTAC degraders","volume":"62","author":"Yang","year":"2019","journal-title":"J Med Chem"},{"key":"R45-20260526","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acschembio.5b00216","article-title":"Selective small molecule induced degradation of the BET bromodomain protein BRD4","volume":"10","author":"Zengerle","year":"2015","journal-title":"ACS Chem Biol"},{"key":"R46-20260526","first-page":"1030","article-title":"A chemical radiculitis model in the rat: establishment and evaluation","volume":"23","author":"Zhao","year":"2019","journal-title":"Zhongguo Zuzhi Gongcheng Yanjiu"},{"key":"R47-20260526","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cbf.3369","article-title":"The PROTAC technology in drug development","volume":"37","author":"Zou","year":"2019","journal-title":"Cell Biochem Funct"}],"container-title":["Neural Regeneration Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/1673-5374.308075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:41:07Z","timestamp":1787845267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1673-5374.308075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,19]]},"references-count":47,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/1673-5374.308075","relation":{},"ISSN":["1673-5374","1876-7958"],"issn-type":[{"value":"1673-5374","type":"print"},{"value":"1876-7958","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,19]]},"assertion":[{"value":"2020-09-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}